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The diagram collects some of the representative polymorphism that have been studied and the pathways in which are involved.
There are strong evidences that correlate inherited cancer syndromes with  a genetic predisposition to therapy-related leukemias.
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CONCLUSIONS
Genetic factors. Genetic predisposition (specifically polymorphic variants) may be involved in the secondary
leukemias development. The main candidates to be responsible of susceptibility are genes implicated in therapy
response:
- Drug detoxification mechanisms: Phase I, Phase II
- DNA repair pathways: Homologous and Non Homologous Recombinational Repair Mechanisms
Figure 3. The diagram collects representative polymorphisms and the pathways in which are involved.
OBJECTIVES & METHODS
Table 1. There are two kinds of drugs administered which can induce the leukemogenic process:
the alkilating agents and the DNA-topoisomerase II inhibitors. The secondary leukemias can be
divided in two groups according to the treatment regimen applied for the previous neoplasia.
Figure 1. The DNA-topoisomerase II
inhibitors arrest the religation process
catalyzed by DNA topoisomerase II and
stabilize the enzyme-DNA convalent
binding. Treatment with these agents
induces chromosomal fragmentation, DNA
deletions and rearrangements, cell cycle
arrest at G2 and activates the apoptotic
pathway. These drugs are considered the
most widely used anticancer agents.
DRUG-DNA INTERACTION
SUSCEPTIBILITY: GENETIC FACTORS 
CHEMOTHERAPEUTIC DRUGS
SUSCEPTIBILITY: CLINICAL FACTORS
The therapy-related leukemias are the direct consequence of mutational events induced by a genotoxic therapy (chemotherapy and/or radiotherapy) used to treat a primary malignancy. Due to the improved survival rates of
many cancers and the increasing use of chemotherapeutic regimes, the incidence of secondary leukemias has risen. The most frequent and widely studied type of secondary leukemia is the therapy-related acute myeloid
leukemia, t-AML (many authors include the therapy-related myelodysplasia, t-MDS, in this clinical entity). The reason why the leukemias are the most frequent secondary neoplasias is because the hematologic cells have
favourable properties for the clonal expansion of one cell with accumulated harmful mutations: they obtain their nutrients directly from the blood and have the ability to migrate through the bloodstream. The incidence of t-AML
varies between 10-20%, and the prognosis is worse than de novo AML. Despite the prompt diagnosis and treatment, the t-AML patients have a 5-year survival rate of less than 10%. It has been described the complex karyotype
at diagnosis such as the strongest prognostic indicator of poor outcome.
t-AML versus de novo AML
The Microsatellite Instability (MSI+) phenotype is more frequent in therapy-related 
leukemias, consequence of Mismatch Repair Mechanisms alterations.
Complete or partial deletion of chromosomes 5 and 7 are more frequent in t-AML 
patients.
T-AML is more refractory to treatment than de novo AML because:
1. The systemic injury caused by prior therapy compromise the ability of these
patients to receive intensive chemotherapy regimen.
2. Prior chemotherapy causes a rapid emergence of multidrug resistant phenotype in
t- AML stem cells.
The chromosome aberrations and gene mutations observed are identical. However, the 
frequencies of these alterations may differ between t-AML and their de novo counterparts.
Age: Exposure to treatment with alkilating agents or DNA-topoisomerase II inhibitors in
childhood does NOT confer increased susceptibility. Early childhood (<3 years) can be a
protector factor against the secondary leukemia development.
Clinical risk factors in therapy based on:
Higher cumulative dose
Older age
Splenectomy
Radiotherapy
Intermittent schedules
Preceding L-asparginase
administration
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 Keywords used were “secondary leukemias”, “t-AML”, 
“therapy-related leukemias”, “alkilating agents”, “DNA 
topoisomerase II inhibitors”
 Articles were selected from 1990-2014
Figure 2. Alkilating agents have reactive
groups that interact covalently to
nucelophilic sites of DNA and produce
direct DNA damage by the creation of
inter- or intrastrand crosslinks (intrastrand
crosslinks appears to be more harmful for
the cell). As a result, induce the adduct
and diadduct formation and it has been
demonstrated that the cytotoxicity is
proporional to diadduct formation. The t-
AML cases after the alkilating agents
exposure are more common.
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OBJECTIVES
 To describe the causes and features of 
therapy-related leukemias. 
 To analyze the leukemogenic effect of 
chemotherapeutic drugs.
INTRODUCTION
There are also strong evidences of the correlation between inherited cancer syndromes and a genetic predisposition 
to therapy-related leukemias: Neurofibromatosis (NF), Li-Fraumeni Syndrome or Fanconi Anemia (FA).
Increased understanding of therapy-related leukemias susceptibility will contribute:
• To prevent its development in patients with certain polymorphisms and risk factors
• To increase the treatment effectiveness (alternative drugs for these patients are being investigated)
PubMed and ScienceDirect
database were the main
sources of information. 
